吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察

目的观察吉西他滨单药治疗老年晚期非小细胞肺癌（NscLc）的临床疗效和不良反应。方法36例晚期NSCLC初治老年患者予吉西他滨1000mg／m^2第1、8天静脉滴注30min，21d为1个周期，治疗2～4个周期，每2个周期评价疗效。结果完全缓解（CR）I例，部分缓解（PR）11例，稳定（SD）10例，进展（PD）14例，总有效率（CR＋PR）33．4％，疾病控制率（CR＋PR＋SD）为61．2％。主要毒副反应为骨髓抑制和血小板减少。结论吉西他滨单药治疗老年晚期NSCLC有效，耐受性好。

Clinical Observation of Gemcitabine in Treating Advanced Non-small Cell Lung Cancer in the Elderly Patients

Objective To evaluate the clinical efficacy and side effects of gemcitabine as single chemotherapy for elderly patients with advanced non-small-cell lung cancer（NSCLC）. Methods Thirty-six elderly patients with advanced NSCLC who were chemotherapy-naivere en- roUed in this study. Gemcitabine At the doses of 1000rag/m2,8 was administrated intravenously every 21 days as a cycle,each patient received 2-4 cycles.The clinical efficacy was evaluated for 2 cycles. Results All of 36 patients could be evaluated, 1 complete response（CR）, 11 partial response（PR）, 10 stable disease（SD ）, 14 progress disease（PD ）. The over-all response rate（CR＋PR） was 33.4% and disease control rate （CR＋PR＋SD）was 61.2%. The main toxicity was myelosuppression and decreasing platelet. Conclusion Single agent Gemcitabine For elderly patients with advanced NSCLC is an efficient and well-tolerated chemotherapeutic approach with a low toxicity level.